PPT-Pregnancy and PrEP : Considerations for HIV

PrEP Products IAS 2016 MTN Symposium Nelly Rwamba Mugo Kenya Medical Research Institute KEMRI University of WashingtonICRC Department of Global Health Partners in Health R esearch and Development PHRD. Adults:. . Implications . for Clinical Practice. PrEP for Heterosexually-Active Women and Men in the U.S.. Dawn K. Smith, MD, MS, MPH. Division of HIV/AIDS Prevention. Centers for Disease Control and Prevention. PrEP. – . The Basics. Module . 2. Session Overview. Who is . PrEP. for?. Contraindications to . PrEP. . PrEP. in pregnancy. Assessing risk. Eligibility criteria. Starting and stopping . PrEP. Condom use and . Clinical trials have shown daily oral . Tenofovir. to effectively prevent HIV acquisition. PrEP must only be prescribed for HIV- patients and patients taking PrEP must have regular tests for HIV and other clinical conditions. . Step 3: Summary Findings. APRIL. 2016. This toolkit is designed to help implementers plan for introduction and roll out of oral . PrEP.. The toolkit enables implementers to 1) catalogue the current situation at the country-level for the introduction of Oral PrEP, 2) identify existing assets and strengths that could be leveraged for PrEP introduction, and 3) highlight gaps in understanding, processes, or resources that will need to be addressed to support successful PrEP introduction. By working through these three steps, implementers will complete a Situation Analysis that can be used to guide planning and preparation for the launch and scale-up of oral . Operative Sequence. Anatomy. Colposcopy. Overall Purpose of Procedure. :. Colposcopy . is a common gynecology follow-up for abnormal Pap smears.. A Pap smear. checks for changes in the cells of the cervix (office procedure).. . . Shorai. . Mukaka. , . MBchB. (. UZ). 05 MAY 2017. Outline. Background. HPTN 082 study. MTN 034 study. IMPAACT 2009 study. Background. There has been global progress in HIV management in the last decade, however, the epidemic remains uncontrolled.. PrEP Considerations for HPX3002/HVTN 706 Susan Buchbinder HVTN Study Chair/San Francisco Site PI PrEP is safe and highly effective against sexual exposures for MSM and TGW 4 Doses/Week has Similar Efficacy to Daily TDF/FTC for MSM Clinical M anagement Module 4 (e) Pregnancy and Breast Feeding What about pregnancy and breastfeeding? Risk of seroconversion during conception and pregnancy 1 PrEP use at conception and during pregnancy by the uninfected partner may offer an additional tool to reduce the risk of sexual HIV PRE-EXPOSURE PROPHYLAXIS in Pregnancy in South Africa Dr. Francesca Conradie President of the Southern African HIV Clinician Society Guideline process in South Africa Southern African HIV Clinicians Society Clinical Updates on . PrEP. , . TasP. & Assisted Reproductive Technologies. 4/23/2018 - UCSF Mission Bay. Monica Hahn & Guy Vandenberg. Outline. Overview of preconception health for . serodifferent. introduction . of . DTG. Nandita Sugandhi. ICAP at Columbia University. No conflicts of interest to declare. Overview. Introducing . DTG in guidelines now. Programmatic Context. Eligible patient populations. Jean Anderson, MD. Professor, Director of Division of Gynecologic Specialties. The Johns Hopkins University. Baltimore, MD. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years. Affairs. Prescribing PrEP in Family Planning Settings. May 20, 2019. 12:00 pm ET. Note: This call will be recorded. Objectives. Outline how to identify PrEP candidates, offer PrEP, and prescribe PrEP. Erika Aaron, CRNP. Disclosures. Successful Completion:. Contact hours will be prorated according to documented attendance. To receive contact hours, participants must complete and submit the on-line evaluation/request for credit form. CNE and CME certificates will be emailed approximately 4 weeks after completion of the evaluation/request for credit form..